Abstract
Lung transplantation is an established treatment option for children and adolescents suffering from end-stage lung diseases refractory to therapy. The primary aims, to prolong life and to improve quality of life, are reached in most cases. Improvements in surgical techniques and perioperative care have led to a relevant decrease of early mortality after lung transplantation, over the last two decades. Nevertheless, long-term survival remains significantly lower compared to other solid organ transplant outcomes. Chronic lung allograft dysfunction (CLAD) is the leading cause of death in lung transplant recipients after the first year from transplantation. Increasing knowledge of pathophysiological processes and risk factors for CLAD have emerged in recent years and new definitions of CLAD subtypes have been proposed. This chapter provides an overview of our current understanding of different forms of allograft dysfunction, their definition criteria and current treatment approaches.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Amin R, Subbarao P, Jabar A et al (2010) Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 65:379–383
Andreu G, Achkar A, Couetil J et al (1995) Extracorporeal photochemotherapy treatment for acute lung rejection episode. J Heart Lung Transplant 14:793–796
Angaswamy N, Tiriveedhi V, Sarma NJ et al (2013) Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol 74:1478–1485
Appel J, Hartwig M, Davis R et al (2005) Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol 66:378–386
Astor T, Weill D, Cool C et al (2005) Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. J Heart Lung Transplant 24:2091–2097
Baum C, Reichenspurner H, Deuse T (2013) Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 32:1270–1271
Becker Y, Samaniego-Picota M, Sollinger H (2006) The emerging role of rituximab in organ transplantation. Transpl Int 19:621–628
Benden C, Speich R, Hofbauer G et al (2008) Extracorporeal photopheresis after lung transplantation: a 10-year single center experience. Transplantation 86:1625–1627
Berry G, Burke M, Andersen C et al (2013) Pathology of pulmonary antibody-mediated rejection: 2012 update from the pathology council of the ISHLT. J Heart Lung Transplant 32:14–21
Burton C, Iversen M, Carlsen J et al (2009) Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant 28:888–893
Clatworthy M (2011) Targeting B cells and antibody in transplantation. Am J Transplant 11:1359–1367
Colvin R, Smith R (2005) Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5:807–817
Cooper J, Billingham M, Egan T et al (1993) A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 12:713
Corris P, Ryan V, Small T et al (2015) A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax 70:442–450
Estenne M, Maurer J, Boehler A et al (2002) Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21:297–310
Faro A, Visner G (2004) The use of multiple transbronchial biopsies as the standard approach to evaluate lung allograft rejection. Pediatr Transplantation 8:322–328
Fehr T, Gaspert A (2012) Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int 25:623–632
Girnita AL, McCurry KR, Iacono AT et al (2004) HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 23:1135–1141
Girnita AL, Duquesnoy R, Yousem SA et al (2005) HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 5:131–138
Goldfarb S, Levvey B, Edwards LB et al (2016) The registry of the International Society for Heart and Lung Transplantation: nineteenth pediatric lung and heart–lung transplantation report – 2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant 35:1196–1205
Hachem RR, Yusen RD, Meyers BF et al (2010) Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 29:973–980
Hopkins P, Aboyoun C, Chhajed P et al (2002) Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 21:1062–1067
Jaramillo A, Smith C, Maruyama T et al (2003) Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 64:521–529
Jordan S, Vo A, Toyoda M et al (2005) Post-transplant therapy with high dose intravenous gammaglobulin: applications to treatment of antibody-mediated rejection. Pediatr Transplant 9:155–161
Jordan S, Toyoda M, Vo A (2011) Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 7:341–348
Kapila A, Baz M, Valentine V et al (2015) Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey. J Heart Lung Transplant 34:65–74
Kingah PL, Muma G, Soubani A (2014) Azithromycin improves lung function in patients with post lung transplant bronchiolitis obliterans syndrome: a meta-analysis. Clin Transpl 28:906–910
Kuehnel M, Maegel L, Vogel-Claussen J et al (2017) Airway remodeling in the transplanted lung. Cell Tissue Res 367:663–675
Marques M, Schwartz J (2011) Update on extracorporeal photopheresis in heart and lung transplantation. J Clin Apheresis 26:146–151
Meyer K, Raghu G, Verleden G et al (2014) An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 44:1479
Morrell M, Pilewski J, Gries C et al (2014) De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant 33:1288–1294
Palmer SM, Davis RD, Hadjiliadis D et al (2002) Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 74:799–804
Rook A, Cohen J (1993) Therapeutic applications of photopheresis. Derm Clin 11:339–347
Saini D, Angaswamy N, Tiriveedhi V et al (2010) Synergistic effect of antibodies to human leukocyte antigens and defensins in pathogenesis of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant 29:1330–1336
Sengsayadeth S, Srivastava S, Jagasia M et al (2012) Time to explore preventive and novel therapies for Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18:1479–1487
Singh N, Pirsch J, Samaniego M (2009) Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 23:34–46
Sivakumar P, Ntolios P, Jenkins G et al (2012) Into the matrix: targeting fibroblasts in pulmonary fibrosis. Curr Opin Pulm Med 18:462–469
Snyder L, Palmer S (2006) Immune mechanisms of lung allograft rejection. Semin Respir Crit Care Med 27:534–543
Snyder L, Gray A, Reynolds J et al (2014) Antibody desensitization therapy in highly sensitized lung transplant candidates. Am J Transplant 14:849–856
Stewart S, Fishbein M, Snell F et al (2007) Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 26:1229–1241
Szczepiorkowski Z, Bandarenko N, Kim H et al (2007) Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis applications Committee of the American Society Apheresis. J Clin Apher 14:106–175
Trulock EP, Christie JD, Edwards LB et al (2007) Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report 2007. J Heart Lung Transplant 26:782–795
Verleden G, Vos R, De Vleeschauwer S et al (2009) Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl in 22:771
Verleden G, Vos R, Verleden S et al (2011) Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 92:703–708
Verleden S, Vos R, Vandermeulen E et al (2013) Involvement of interleukin-17 during lymphocytic bronchiolitis in lung transplant patients. J Heart Lung Transplant 32:447–453
Verleden G, Raghu G, Meyer K et al (2014) A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant 33:127
Verleden S, Ruttens D, Vandermeulen E et al (2015a) Restrictive chronic lung allograft dysfunction: where are we now? J Heart Lung Transplant 34:625–630
Verleden G, Vos R, Vanaudenaerde B et al (2015b) Current views on chronic rejection after lung transplantation. Transpl Int 28:1131–1139
Vo A, Petrozzino J, Yeung K et al (2013) Efficacy, outcomes, and cost effectiveness of desensitization using IVIG and rituximab. Transplantation 95:852–858
Vos R, Vanaudenaerde B, Verleden S et al (2011) A randomized controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 37(1):164–172
Vos R, Vanaudenaerde B, Verleden S et al (2012) Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation 94:101–109
Vos R, Verleden S, Ruttens D et al (2013) Pirfenidone: a potential new therapy for restrictive allograft syndrome? Am J Transplant 13:3035–3040
Vos R, Vereleden S, Verleden G (2015) Chronic lung allograft dysfunction: evolving practice. Curr Opin Organ Transplant 20:483–91
Welsh CH, Wang TS, Lyu DM et al (2015) An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation. Revis Ann Am Thorac Soc 12:118–119
Wong J, Westall G, Snell F (2015) Bronchoscopic procedures and lung biopsies in Pediatric lung transplant recipients. Pediatr Pulmonol 50:1406–1419
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Conrad, C., Schwerk, N. (2018). Allograft Dysfunction. In: Dunn, S., Horslen, S. (eds) Solid Organ Transplantation in Infants and Children. Organ and Tissue Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-07284-5_72
Download citation
DOI: https://doi.org/10.1007/978-3-319-07284-5_72
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-07283-8
Online ISBN: 978-3-319-07284-5
eBook Packages: MedicineReference Module Medicine